To Director Redfield and Chairman Romero:
“The new science leaves little doubt that there should be no distinction between individuals with Type 1 and Type 2 diabetes mellitus, given the common, heightened risk both groups face for the most severe health outcomes of COVID-19. In light of this information, we urge you to take immediate steps to update CDC’s guidance, reflecting this equal risk. Doing so is particularly important and time-sensitive, as states are now operationalizing vaccine rollouts and it would be problematic for any state to differentiate between Type 1 and Type 2 DM in their prioritization of access for vaccines."
Read the Full Letter
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.
